
    
      Background: Montelukast is a potent, specific, orally active, cysteinyl leukotriene receptor
      antagonist with a rapid onset of action.

      Objective: To evaluate the effect of the addition of a single dose of oral montelukast to
      standard therapy in acute asthma. Design: Double-blind, randomised, controlled, parallel
      group trial. Setting: Pediatric service of Education and training Hospital Patients: Children
      with the ages of 6-60 months who were hospitalized for acute asthma Intervention: Children
      received montelukast 4 mg or placebo orally in addition to the standard therapy. Clinical
      asthma score was recorded before administering study medication and thereafter, 4 hourly
      until discharge. Main outcome measure: The primary outcome was discharge rates.
    
  